MedPath

A study for Efficacy and Safety of Metronomic Administration of Detoxification Chinese Herbs combined with Thalidomide in the Treatment of Elderly or Refractory Relapsed Lymphoma

Phase 4
Recruiting
Conditions
Relapsed or Refractory Non-Hodgkin's lymphoma
Registration Number
ITMCTR1900002282
Lead Sponsor
Shanghai Municiple hospital of Traditional Chinese Medicine
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Recruiting
Sex
All
Target Recruitment
Not specified
Inclusion Criteria

1. Meet the pathological diagnostic criteria of lymphoma (pathological types are not limited);
2. Meet the diagnostic criteria for elderly or refractory or relapsed;
3. Patients assessed as inappropriate or intolerable or unwilling to receive combination chemotherapy and targeted therapy;
4. ECOG=3;
5. Survival is expected to be greater than 3 months;
6. Having signed the informed consent.

Exclusion Criteria

1. Aged<18 years;
2. Pregnant or lactating women;
3. History of thrombosis nearly 2 years;
4. Allergic or allergic to various drugs;
5. Severe liver and kidney dysfunction;
6. With severe infection or difficult to control;
7. Taking other traditional Chinese medicine or taking other clinical trials nearly 2 weeks;
8. The investigators concluded that patients should not take any other part of the study.

Study & Design

Study Type
Interventional study
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Quality of Life Assessment;TCM symptom score;VEGF;Tumor volume;
Secondary Outcome Measures
NameTimeMethod
ß2 microglobulin;LDH;
© Copyright 2025. All Rights Reserved by MedPath